胶质瘤治疗中适应性进化的利用。
Exploitation of adaptive evolution in glioma treatment.
作者信息
Cordner Ryan, Black Keith L, Wheeler Christopher J
出版信息
CNS Oncol. 2013 Mar;2(2):171-9. doi: 10.2217/cns.12.46.
Abstract
Glioblastoma multiforme (GBM) is a malignant neoplasm of the CNS with almost uniform lethality. Even with standard-of-care treatments, the prognosis for patients remains dismal. GBM, as with other malignancies, often acquires treatment resistance after an initial response to therapy. Treatment resistance may come about through the adaptive evolution of tumors in response to selection pressures from treatment interventions and the microenvironment. This review discusses how adaptive evolution might potentially be exploited as a new paradigm in GBM treatment.
摘要
多形性胶质母细胞瘤（GBM）是一种中枢神经系统的恶性肿瘤，致死率几乎一致。即使采用标准治疗方案，患者的预后仍然很差。与其他恶性肿瘤一样，GBM在对治疗产生初始反应后通常会产生耐药性。耐药性可能是由于肿瘤在治疗干预和微环境的选择压力下适应性进化而产生的。本综述讨论了适应性进化如何有可能被用作GBM治疗的新范式。
相似文献
1
Exploitation of adaptive evolution in glioma treatment.胶质瘤治疗中适应性进化的利用。
CNS Oncol. 2013 Mar;2(2):171-9. doi: 10.2217/cns.12.46.
2
[Rare clinical form of glioblastoma multiforme].[多形性胶质母细胞瘤的罕见临床形式]
Postepy Hig Med Dosw (Online). 2014 Mar 27;68:316-24. doi: 10.5604/17322693.1095834.
3
DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.DNA 损伤反应和生长因子信号通路在神经胶质瘤发生和治疗抵抗中的作用。
Cancer Res. 2011 Sep 15;71(18):5945-9. doi: 10.1158/0008-5472.CAN-11-1245. Epub 2011 Sep 13.
4
Glioblastoma multiforme: a review of where we have been and where we are going.多形性胶质母细胞瘤：回顾过去与展望未来。
Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83. doi: 10.1517/13543780903052764.
5
Glioblastoma antigen discovery--foundations for immunotherapy.胶质母细胞瘤抗原发现——免疫治疗的基础
J Neurooncol. 2015 Jul;123(3):347-58. doi: 10.1007/s11060-015-1836-8. Epub 2015 Jun 5.
6
Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.用分泌γ干扰素的肿瘤细胞进行免疫接种可消除已完全形成且具有侵袭性的大鼠胶质瘤。
J Immunother. 2009 Jul-Aug;32(6):593-601. doi: 10.1097/CJI.0b013e3181a95148.
7
Current Immunotherapies for Glioblastoma Multiforme.目前用于多形性胶质母细胞瘤的免疫疗法。
Front Immunol. 2021 Mar 9;11:603911. doi: 10.3389/fimmu.2020.603911. eCollection 2020.
8
Immunotherapy targeting glioma stem cells--insights and perspectives.针对神经胶质瘤干细胞的免疫疗法——见解与展望。
Expert Opin Biol Ther. 2012 Feb;12(2):165-78. doi: 10.1517/14712598.2012.648180. Epub 2011 Dec 26.
9
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.免疫检查点调节剂：新兴的抗肿瘤武器。
J Immunol Res. 2016;2016:4683607. doi: 10.1155/2016/4683607. Epub 2016 Jan 4.
10
Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells.TRAIL 与放疗协同消除脑胶质瘤干细胞。
Clin Exp Med. 2018 Aug;18(3):399-411. doi: 10.1007/s10238-018-0504-7. Epub 2018 May 18.
引用本文的文献
1
Glycosylated Delphinidins Decrease Chemoresistance to Temozolomide by Regulating NF-κB/MGMT Signaling in Glioblastoma.糖基化飞燕草色素通过调节胶质母细胞瘤中的NF-κB/MGMT信号通路降低对替莫唑胺的化疗耐药性。
Cells. 2025 Jan 24;14(3):179. doi: 10.3390/cells14030179.
2
Potassium Ion Channels in Malignant Central Nervous System Cancers.恶性中枢神经系统肿瘤中的钾离子通道
Cancers (Basel). 2022 Sep 29;14(19):4767. doi: 10.3390/cancers14194767.
3
Glioblastoma: Current Status, Emerging Targets, and Recent Advances.胶质母细胞瘤：现状、新兴靶点及最新进展。
J Med Chem. 2022 Jul 14;65(13):8596-8685. doi: 10.1021/acs.jmedchem.1c01946. Epub 2022 Jul 5.
4
Progression Patterns in Non-Contrast-Enhancing Gliomas Support Brain Tumor Responsiveness to Surgical Lesions.非增强性胶质瘤的进展模式支持脑肿瘤对手术损伤的反应性。
Pathol Oncol Res. 2022 May 30;28:1610268. doi: 10.3389/pore.2022.1610268. eCollection 2022.
5
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.胶质母细胞瘤中替莫唑胺耐药的机制——综述
Cancer Drug Resist. 2021;4(1):17-43. doi: 10.20517/cdr.2020.79. Epub 2021 Mar 19.
6
The miR-200 family: multiple effects on gliomas.微小RNA-200家族：对神经胶质瘤的多种作用
Cancer Manag Res. 2018 Jul 13;10:1987-1992. doi: 10.2147/CMAR.S160945. eCollection 2018.
7
Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma.SOX2和miR-200b表达与胶质瘤患者临床病理特征及预后的相关性
Exp Ther Med. 2015 Jul;10(1):88-96. doi: 10.3892/etm.2015.2488. Epub 2015 May 12.
本文引用的文献
1
Association between prediagnostic IgE levels and risk of glioma.诊断前 IgE 水平与胶质瘤风险的关联。
J Natl Cancer Inst. 2012 Aug 22;104(16):1251-9. doi: 10.1093/jnci/djs315. Epub 2012 Aug 1.
2
Current strategies for identification of glioma stem cells: adequate or unsatisfactory?当前鉴定神经胶质瘤干细胞的策略：足够或不满意？
J Oncol. 2012;2012:376894. doi: 10.1155/2012/376894. Epub 2012 May 23.
3
Mutational processes molding the genomes of 21 breast cancers.21 例乳腺癌基因组的突变过程。
Cell. 2012 May 25;149(5):979-93. doi: 10.1016/j.cell.2012.04.024. Epub 2012 May 17.
4
The life history of 21 breast cancers.21 例乳腺癌的生命史。
Cell. 2012 May 25;149(5):994-1007. doi: 10.1016/j.cell.2012.04.023. Epub 2012 May 17.
5
Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence.分析胶质母细胞瘤患者两次复发中的突变异质性。
PLoS One. 2012;7(4):e35262. doi: 10.1371/journal.pone.0035262. Epub 2012 Apr 20.
6
Clonal competition with alternating dominance in multiple myeloma.多发性骨髓瘤中具有交替优势的克隆竞争。
Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.
7
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.脑微环境优先增强 CD133(+)脑胶质瘤干细胞样细胞的放射抵抗性。
Neoplasia. 2012 Feb;14(2):150-8. doi: 10.1593/neo.111794.
8
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.单细胞外显子组测序揭示肾脏肿瘤的单核苷酸突变特征。
Cell. 2012 Mar 2;148(5):886-95. doi: 10.1016/j.cell.2012.02.025.
9
IDH mutation impairs histone demethylation and results in a block to cell differentiation.IDH 突变会损害组蛋白去甲基化，导致细胞分化受阻。
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
10
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.IDH1 突变足以建立起胶质瘤高甲基化表型。
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
Zotero 插件